This trial studies the accuracy of eye injections with a new drug, ABP 938, compared to an existing drug, aflibercept.
- Chorioretinal Vascular Disease
2 Primary · 3 Secondary · Reporting Duration: Up to 35 Days
2 Treatment Groups
1 of 2
1 of 2
48 Total Participants · 2 Treatment Groups
Primary Treatment: ABP 938 · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18 - 99 · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is there an upper age limit for potential participants in this research?
"As per the eligibility requirements for this trial, the age range accepted is 18 to 99." - Anonymous Online Contributor
What safety precautions are necessary when administering ABP 938 to patients?
"We rate ABP 938's safety at a 3 on the scale of 1-3 due to its Phase 3 status and evidence both for efficacy and multiple rounds of data proving its security." - Anonymous Online Contributor
Are there currently any vacancies in this experiment for volunteers?
"Per clinicaltrials.gov, the trial that was initially posted on 1/23/2023 is currently recruiting participants. This information has been recently updated as of 2/10/2023." - Anonymous Online Contributor
What is the current tally of facilities conducting this clinical trial?
"There are 4 clinical trial sites that have begun recruiting patients, such as the Bellaire Retina Center in Texas, San Antonio's Retina Centre and The Woodlands' Retinal Consultants of Texas." - Anonymous Online Contributor
How many participants are currently enrolled in this research initiative?
"Affirmative. According to the clinicaltrials.gov portal, this medical trial is searching for 48 participants across 4 sites and was initially posted on January 23rd 2023 with a later update occurring on February 10th of that same year." - Anonymous Online Contributor
What are the eligibility requirements for participation in this trial?
"The study requires 48 individuals who have chorioretinal vascular disease and are between 18-99 years of age. The key criteria for applicants include signing an approved informed consent form, being male or female over the age of eighteen, and having neovascular age-related [macular degeneration](https://www.withpower.com/clinical-trials/macular-degeneration), diabetic macular edema, macular edema due to retinal vein occlusion or diabetic retinopathy in one eye (with treatment not necessary)." - Anonymous Online Contributor